4-(吗啉-4-磺酰基)-苯甲酰氯 | 654682-86-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(吗啉-4-磺酰基)-苯甲酰氯
• 英文名称: 4-(morpholine-4-sulfonyl)-benzoyl chloride
• 英文别名: 4-(morpholinosulphonyl)benzoylchloride；4-morpholin-4-ylsulfonylbenzoyl chloride
• CAS: 654682-86-7
• 化学式: C₁₁H₁₂ClNO₄S
• 分子量: 289.74
• InChiKey: UKILBGHYXVLCGS-UHFFFAOYSA-N

物化性质

• 沸点：
  445.1±55.0 °C(Predicted)
• 密度：
  1.432±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 包装等级：
  II
• 危险类别：
  6.1,8
• 危险性防范说明：
  P260,P264,P270,P271,P280,P301+P330+P331,P302+P352,P303+P361+P353,P304+P340,P305+P351+P338,P310,P403+P233,P405,P501
• 危险品运输编号：
  2928
• 危险性描述：
  H301,H311,H314,H331

反应信息

• 作为反应物：
  描述：

  4-(吗啉-4-磺酰基)-苯甲酰氯 在 sodium azide 作用下， 以 水 、 丙酮 为溶剂， 生成 4-(morpholine-4-sulfonyl)-benzoyl azide
  参考文献：
  名称：

  取代的氨基甲酸酯的合成及其抗真菌活性。

  摘要：

  DOI：

  10.1021/jm00293a029
• 作为产物：
  描述：

  4-(4-磺酰基吗啉)-苯甲酸 在 氯化亚砜 作用下， 以 氯仿 为溶剂， 反应 1.0h， 生成 4-(吗啉-4-磺酰基)-苯甲酰氯
  参考文献：
  名称：

  具有抗血小板活性的新型嘌呤

  摘要：

  四种嘌呤 - 2,6 - 二胺，4a, b, 5a, b，十九种 N-（嘌呤 - 2 - 基）苯甲酰胺 6a - q, 7b 和一种 N-（嘌呤 - 2 - 基） -2 - 呋喃甲酰胺 8首次制备并测试它们对血小板聚集的抑制作用。6a、b、h、m、o、p六种化合物在Born试验中抑制胶原诱导的血小板聚集，IC50值在3～10μmol/L之间。ADP、PAF和肾上腺素被用作特异性聚集诱导剂来检查抗聚集活性的机制。观察到惊人的纳米摩尔级活动模式，6m、7b、8 甚至亚纳摩尔范围（6b）。化合物6b以IC50 = 0.45 nM（6m：3.5 nM；8：30 nM）抑制ADP诱导的血小板聚集。化合物 7b 显示出对诱导剂肾上腺素的拮抗作用，IC 50 = 1.8 nM (6o: 20 nM; 8: 30 nM)。

  DOI：

  10.1002/ardp.200500189

文献信息

• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSES CHIMIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2004011410A1

  公开（公告）日：2004-02-05

  Compounds of formula (I):wherein variable groups are as defined within; for use in the inhibition of 11βHSD1 are described.

  式(I)的化合物：其中变量基团如定义内；用于抑制11βHSD1。
• Ketones
  申请人：Barton John Peter

  公开号：US20050272036A1

  公开（公告）日：2005-12-08

  Compounds of formula (I): wherein variable groups are as defined within; for use in the inhibition of 11βHSD1 are described.

  描述了式(I)的化合物：其中变量基团如定义的那样；用于抑制11βHSD1。
• Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor
  作者：Patrick R. Maloney、Pasha Khan、Michael Hedrick、Palak Gosalia、Monika Milewski、Linda Li、Gregory P. Roth、Eduard Sergienko、Eigo Suyama、Eliot Sugarman、Kevin Nguyen、Alka Mehta、Stefan Vasile、Ying Su、Derek Stonich、Hung Nguyen、Fu-Yue Zeng、Arianna Mangravita Novo、Michael Vicchiarelli、Jena Diwan、Thomas D.Y. Chung、Layton H. Smith、Anthony B. Pinkerton

  DOI：10.1016/j.bmcl.2012.08.105

  日期：2012.11

  The recently discovered apelin/APJ system has emerged as a critical mediator of cardiovascular homeostasis and is associated with the pathogenesis of cardiovascular disease. A role for apelin/APJ in energy metabolism and gastrointestinal function has also recently emerged. We disclose the discovery and characterization of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221), a potent APJ functional antagonist in cell-based assays that is >37-fold selective over the closely related angiotensin II type 1 (AT1) receptor. ML221 was derived from an HTS of the similar to 330,600 compound MLSMR collection. This antagonist showed no significant binding activity against 29 other GPCRs, except to the kappa-opioid and benzodiazepinone receptors (<50/<70%I at 10 mu M). The synthetic methodology, development of structure-activity relationship (SAR), and initial in vitro pharmacologic characterization are also presented. (C) 2012 Elsevier Ltd. All rights reserved.
• ——
  作者：I. L. Odinets

  DOI：10.1023/a:1023906822755

  日期：——

  Under conditions of the phase transfer catalysis, acylation of (thio)phosphorylacetonitriles by (het)aroyl chlorides affords the Z-enol forms of C-acylation products in high yields. Their configurations were studied by IR spectroscopy, dipole moment measurements, and ab initio quantum-chemical calculations [B3LYP/6-31G(d)]. The C=C double bond and the phosphoryl or thiophosphoryl group have an s-cis arrangement. The possibility of strong intramolecular hydrogen bonding in these conformers is the governing factor responsible for the three-dimensional structures of the compounds under investigation. Derivatives of nicotinic acid existing in the individual form as zwitterions are the only exceptions.
• KETONES
  申请人：AstraZeneca AB

  公开号：EP1549600A1

  公开（公告）日：2005-07-06